If you are looking for big returns and have a high tolerance for risk, then read on.
That's because listed below is one ASX share that Bell Potter believes could rocket higher over the next 12 months.
Image source: Getty Images
Which ASX All Ords share?
The share that has caught the eye of Bell Potter is Aroa Biosurgery Ltd (ASX: ARX).
It is a commercial stage medical device company that operates within the wound care and soft tissue reconstruction sector.
Bell Potter was pleased to see that the company has successfully completed a prospective randomised controlled trial for Symphony in diabetic foot ulcers.
It highlights that the "preliminary results [are] indicating the primary endpoint of complete wound closure at 12 weeks was met."
This is good news because the Symphony product could have a billion-dollar market opportunity. It commented:
Although the full dataset remains due in Q3 FY27, the readout provides important clinical validation ahead of Symphony's commercial launch and supports its positioning under a tougher coverage framework. That early validation arrives as the CY26 CMS reimbursement reset continues to disrupt the US skin substitute market.
The new US$127.14/cm² flat rate has compressed the elevated pricing underpinning many legacy products, with Organogenesis and MiMedx both reporting wound-care revenue declines of at least 60% in Q1 CY26 and consensus expecting pressure to persist through the year. We estimate market size in outpatient care at greater than US$1b.
Time to buy
According to the note, the broker has retained its buy rating and $1.09 price target on the ASX All Ords share. Based on its current share price of 58.5 cents, this implies potential upside of 86% for investors over the next 12 months.
Touching on its outlook and investment thesis, Bell Potter said:
Beyond the clinical readouts, 2H CY26 should bring further clarity on the reimbursement environment. Key watchpoints should include the final PFS and OPPS rules following CMS's proposal to retain the current flat-rate methodology for CY27, while any revised DFU/VLU LCDs could further raise the evidence threshold and narrow the reimbursable product set.
Investment thesis: Buy; TP $1.09 (unchanged) The Myriad growth story remains intact and the outlook for Symphony revenues continues to improve. We make no changes to earnings and maintain our Buy rating and PT of $1.09.
This could make Aroa Biosurgery worth considering if you are looking for exposure to the healthcare sector.
